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Abstract
Purpose—There is scarce information on whether digital screening mammography performance 
differs between black and white women.
Methods—We examined 256,470 digital screening mammograms performed from 2005–2010 
among 31,654 black and 133,152 white Carolina Mammography Registry participants aged ≥40 
years. We compared recall rate, sensitivity, specificity, and positive predictive value (PPV1) 
between black and white women, adjusting for potential confounders using random effects logistic 
regression.
Results—Breast cancer was diagnosed in 276 black and 1,095 white women. Recall rates were 
similar for blacks and whites (8.6% vs. 8.5%), as were sensitivity (83.7% vs. 82.4%), specificity 
(91.8% vs. 91.9%) and PPV1 (4.8% vs. 5.3%) (all p-values>0.05). Stratified and adjusted models 
showed similar results. Despite comparable mammography performance, tumors diagnosed in 
black women were more commonly poorly differentiated and hormone receptor-negative.
Conclusion—Equivalent performance of digital screening mammography by race suggests that 
efforts to understand tumor disparities should focus on etiologic factors that influence tumor 
biology.
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Black women experience higher breast cancer mortality rates than white women and 
typically present with more aggressive tumors and worse prognosis, even after taking stage 
at diagnosis into account.[1] Mammography screening is commonly associated with the 
diagnosis of smaller, earlier stage tumors, suggesting that racial differences in screening-
related tumor detection may influence racial differences in the tumor characteristics. Only 
one prior study assessed differences in screening mammography performance among blacks 
and whites; however, that study was limited to film-screen mammography, which has 
largely been replaced with digital mammography in the United States.[2] Compared with 
film-screen mammography, digital mammography detects more ductal carcinoma in situ 
(DCIS)[3] and has improved performance among women with dense breasts, ages <50 
years, or who are premenopausal.[4] Age-specific breast cancer rates and mammographic 
density vary between black and white women, [5–7] but it is unknown whether there are any 
racial differences in digital mammography screening performance. Hence, we sought to 




We utilized data from the Carolina Mammography Registry (CMR), a prospective 
population-based breast imaging registry in 39 counties in North Carolina. This study 
received Institutional Review Board approval for passive consenting process to enroll 
participants, link and pool data, and perform analysis. All procedures were Health Insurance 
Portability and Accountability Act compliant. At the time of the mammogram, women 
provided information related to demographics and breast health history. For each 
mammography examination the radiologist recorded the reason for the visit, imaging 
examination performed, Breast Imaging Reporting and Data System (BI-RADS) breast 
density [8], BI-RADS mammogram assessment [8], and follow-up recommendations. 
Patient and radiologist data were linked to breast cancer cases from the North Carolina 
Central Cancer Registry (NCCCR) and to statewide hospital pathology data. Tumor 
behavior (in situ or invasive), grade, stage at diagnosis, size, nodal status, estrogen receptor 
(ER) and progesterone receptor (PR) expression were abstracted from NCCCR and 
pathology reports.
Study Population and Definitions
In this analysis, we examined all digital screening mammograms performed from 2005 to 
2010 among black and white women ages ≥40 years with no personal history of breast 
cancer or history of breast augmentation. Screening mammograms were defined as those 
that were: (i) bilateral; (ii) performed in asymptomatic women; (iii) defined as a “routine 
screen” by the radiologist; and (iv) >9 months after any prior breast imaging. Positive 
screening mammograms had an initial BI-RADS assessment code of 0 (needs additional 
imaging evaluation), 4 (suspicious abnormality), 5 (highly suggestive of malignancy), or 3 
(probably benign finding) when the 3 was associated with a recommendation for immediate 
Henderson et al. Page 2













follow-up. Negative screening mammograms had an initial BI-RADS assessment of 1 
(negative), 2 (benign finding), or 3 with a recommendation for follow-up of >6 months.[9] 
Positive disease status was defined by diagnosis of DCIS or invasive breast cancer within 12 
months of the screening mammogram. Each mammogram was categorized as true positive, 
false negative, true negative, and false positive according to the BI-RADS assessment and 
the cancer outcome.
Statistical Analysis
We computed mammography sensitivity, specificity, positive predictive value (PPV1), and 
recall rate using standard definitions [10] and compared the statistics for black and white 
women using an F test. We used a random effects logistic regression model to adjust for 
differences between radiologists interpreting the images and to account for correlated 
observations within women who had multiple screening examinations during the study 
period.[11] We adjusted for age at mammogram, rural/urban residence, education, 
menopausal status, breast density, prior breast biopsy, family history of breast cancer, and 
time since last screening examination. We present comparisons overall and stratified by age 
group and BI-RADS breast density (dichotomized into almost entirely fat or scattered 
fibroglandular densities versus heterogeneously dense or extremely dense). We also 
compared tumor characteristics by race using the chi-square test, for all cancers and also 
stratified by true positive or false negative status.
Results
Of 256,470 digital screening mammograms, 56,239 (21.9%) were performed among black 
women and 200,231 (78.1%) were performed among white women (Table 1). The majority 
of women were ages 40–59 years, lived in urban areas, were post-menopausal, had no prior 
breast biopsy, and no family history of breast cancer. The proportion of black women with 
some college of higher education was 43.9% compared with 60.1% for white women. BI-
RADS breast density of heterogeneously or extremely dense was 40.6% for black women 
versus 48.0% for white women.
A total of 1,371 breast cancers were diagnosed, including 231 true positives and 45 false 
negatives among blacks and 902 true positives and 193 false negatives among whites. The 
number of false positives was 4,607 for blacks and 16,099 for whites. The overall recall rate 
was 8.5%, sensitivity was 82.6%, specificity was 91.9%, and PPV1 was 5.1%, similar to 
digital mammography performance previously reported among women in the Breast Cancer 
Surveillance Consortium.[12] The recall rate, sensitivity, specificity, and PPV1 were similar 
for blacks and whites in both crude (Table 2) and adjusted models (p-values for adjusted 
rates were 0.1773, 0.4869, 0.3194, and 0.3992, respectively). Furthermore, stratification by 
age group or breast density did not reveal any differences in performance by race.
Although performance was similar between blacks and whites, black women were 
diagnosed with significantly higher proportions of DCIS with comedo necrosis (p-
value=0.04), poorly differentiated invasive tumors (p-value=0.024), and ER-negative (p-
value<0.001) and PR-negative (p-value=0.004) tumors (Table 3). There was limited power 
to evaluate whether racial differences in tumor characteristics by race differed if the tumor 
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was detected by mammography or not (true positive versus false negative); however, racial 
disparities in tumor grade, ER, and PR expression were similar for true positive and false 
negative tumors.
Conclusions
Our finding of no difference in the performance of digital screening mammography between 
black and white women, even after controlling for possible confounders, is in agreement 
with a previous report of no difference in film-screen mammography performance by race.
[2] Although we found the performance was similar, the types of tumors identified by digital 
screening mammography differed by race. As has been reported in previous studies of film-
screen detected breast cancers, black women were more likely to be diagnosed with higher 
grade tumors among both DCIS and invasive lesions and with ER or PR-negative tumors 
[1], suggesting that these differences are likely not caused by the rate of screening-related 
detection. Our study is the first to compare the performance of digital mammography by 
race and included over 160,000 women with over 1,300 breast cancers. Future work seeking 
to explain racial differences in tumor characteristics in a screening population should focus 
on etiologic risk factors that may influence tumor biology.
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Table 1






N % N %
Age Group
 40–49 16,391 29.2 52,034 26.0
 50–59 18,560 33.0 56,395 28.2
 60–69 12,505 22.2 50,868 25.4
 70–79 6,815 12.1 31,037 15.5
 80+ 1,968 3.5 9,897 4.9
Rural/Urban Residence
 Rural 14,238 25.3 58,944 29.4
 Urban 41,995 74.7 141,282 70.6
 Missing 6 --- 5 ---
Educational Level
 < High school 3,380 18.8 5,726 7.3
 High school graduate 6,717 37.3 25,650 32.6
 Some college/technical school 4,574 25.4 24,194 30.8
 College graduate 3,318 18.4 23,120 29.4
 Missing 38,250 --- 121,541 ---
Menopausal Status
 Pre or peri menopausal 19,877 35.5 62,131 31.1
 Post menopausal 36,162 64.5 137,467 68.9
 Missing 200 --- 633 ---
BIRADS Breast Density*
 Almost entirely fat 4,958 9.2 13,316 7.0
 Scattered fibroglandular densities 27,199 50.3 85,963 45.1
 Heterogeneously dense 20,063 37.1 79,992 41.9
 Extremely dense 1,877 3.5 11,558 6.1
 Missing 2,142 --- 9,402 ---
Prior Breast Biopsy
 Yes 10,637 23.9 46,346 25.9
 No 33,954 76.2 132,758 74.1
 Missing 11,648 --- 21,127 ---
Family History of Breast Cancer
 Yes 6,789 12.1 28,168 14.1
 No 49,241 87.9 171,643 85.9
 Missing 209 --- 420 ---
*
BI-RADS breast density refers to the Breast Imaging Reporting and Data System
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Table 2




% (95% CI) % (95% CI)
All mammograms
 Recall Rate 8.6 (8.4, 8.8) 8.5 (8.4, 8.6)
 Sensitivity 83.7 (79.3, 88.1) 82.4 (80.1, 84.6)
 Specificity 91.8 (91.5, 92.0) 91.9 (91.8, 92.0)
 PPV1 4.8 (4.2, 5.4) 5.3 (5.0, 5.6)
Stratified by age at mammogram:
40–49 years
 Recall Rate 10.9 (10.4, 11.3) 10.9 (10.6, 11.1)
 Sensitivity 81.8 (70.4, 93.2) 78.8 (72.4, 85.1)
 Specificity 89.3 (88.9, 89.8) 89.3 (89.1, 89.6)
 PPV1 2.0 (1.4, 2.7) 2.3 (1.8, 2.6)
50–59 years
 Recall Rate 8.3 (7.9, 8.6) 8.3 (8.0, 8.5)
 Sensitivity 76.9 (67.6, 86.3) 81.1 (76.3, 86.0)
 Specificity 92.0 (91.7, 92.4) 92.1 (91.8, 92.3)
 PPV1 3.9 (3.0, 4.9) 4.3 (3.8, 4.9)
60–69 years
 Recall Rate 7.5 (7.0, 7.9) 7.7 (7.4, 7.9)
 Sensitivity 85.6 (78.6, 92.6) 84.1 (80.3, 88.0)
 Specificity 93.2 (92.7, 93.6) 92.9 (92.6, 93.1)
 PPV1 8.9 (7.1, 10.7) 7.5 (6.6, 8.3)
≥70 years
 Recall Rate 6.8 (6.3, 7.3) 6.8 (6.6, 7.0)
 Sensitivity 91.2 (83.9, 98.6) 83.2 (79.3, 87.2)
 Specificity 93.8 (93.3, 94.3) 93.8 (93.6, 94.1)
 PPV1 8.7 (6.5, 11.0) 10.2 (9.1, 11.3)
Stratified by breast density:
Almost entirely fat or scattered fibroglandular densities
 Recall Rate 7.4 (7.1, 7.7) 7.1 (7.0, 7.3)
 Sensitivity 86.4 (80.9, 91.9) 85.1 (82.0, 88.2)
 Specificity 93.0 (92.7, 93.2) 93.3 (93.1, 93.4)
 PPV1 5.3 (4.4, 6.2) 6.1 (5.6, 6.7)
Heterogeneously dense or extremely dense
 Recall Rate 10.1 (9.7, 10.5) 9.9 (9.7, 10.1)
 Sensitivity 80.8 (73.8, 87.9) 79.8 (76.4, 83.2)
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Race
Black White
% (95% CI) % (95% CI)
 Specificity 90.3 (89.9, 90.7) 90.5 (90.3, 90.7)
 PPV1 4.4 (3.5, 5.2) 4.7 (4.3, 5.2)
PPV1 = positive predictive value; CI = confidence interval
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